HOLX - Hologic, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Marlborough,
United States
Type: Equity
HOLX price evolution
HOLX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 30 Apr 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2439.1 | $2180 | $1932.1 | |
| Short term investments | ||||
| Net receivables | $600.4 | $628.5 | $647.1 | $670.9 |
| Inventory | $679.8 | $665.5 | $649.2 | $633.6 |
| Total current assets | $3823.3 | $3997 | $3788.7 | $3494.2 |
| Long term investments | ||||
| Property, plant & equipment | $537.8 | $528.8 | $524.8 | $527 |
| Goodwill & intangible assets | $3978.7 | $4044.3 | $4138.6 | |
| Total noncurrent assets | $4893.1 | $4925.7 | $4975.3 | |
| Total investments | ||||
| Total assets | $9156 | $8890.1 | $8714.4 | $8469.5 |
| Current liabilities | ||||
| Accounts payable | $786.8 | $202 | $911.7 | $183.8 |
| Deferred revenue | $233.8 | $222.8 | $204.8 | |
| Short long term debt | $40.7 | $40.6 | $40.6 | |
| Total current liabilities | $1037.2 | $1002.4 | $954.6 | $899 |
| Long term debt | $2497.1 | $2518.5 | $2527.9 | $2537.4 |
| Total noncurrent liabilities | $2936.8 | $2915.4 | $2916.7 | |
| Total debt | $2559.2 | $2568.5 | $2578 | |
| Total liabilities | $4026 | $3939.2 | $3870 | $3815.7 |
| Shareholders' equity | ||||
| Retained earnings | $2845.8 | $2667.2 | $2472.7 | $2302.8 |
| Other shareholder equity | $5130 | -$139.5 | -$137 | -$118.8 |
| Total shareholder equity | $4950.9 | $4844.4 | $4653.8 | |
| (in millions $) | 28 Oct 2024 | 30 Oct 2023 | 24 Oct 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2722.5 | $2339.5 | $1170.3 | |
| Short term investments | ||||
| Net receivables | $600.4 | $625.6 | $617.6 | $942.7 |
| Inventory | $679.8 | $617.6 | $623.7 | $501.2 |
| Total current assets | $3823.3 | $4184.5 | $3862 | $3168.7 |
| Long term investments | ||||
| Property, plant & equipment | $537.8 | $517 | $481.6 | $564.7 |
| Goodwill & intangible assets | $4169.9 | $4517.1 | $4940.8 | |
| Total noncurrent assets | $4954.8 | $5209.2 | $5751.2 | |
| Total investments | ||||
| Total assets | $9156 | $9139.3 | $9071.2 | $8919.9 |
| Current liabilities | ||||
| Accounts payable | $786.8 | $712.9 | $197.7 | $215.9 |
| Deferred revenue | $213 | $195.9 | $218.3 | |
| Short long term debt | $290.1 | $18.2 | $316.7 | |
| Total current liabilities | $1037.2 | $1207.3 | $937.7 | $1326.8 |
| Long term debt | $2497.1 | $2531.2 | $2808.4 | $2735 |
| Total noncurrent liabilities | $2915.1 | $3257.3 | $3374.5 | |
| Total debt | $2836.6 | $2844.6 | $3051.7 | |
| Total liabilities | $4026 | $4122.4 | $4195 | $4701.3 |
| Shareholders' equity | ||||
| Retained earnings | $2845.8 | $2056.3 | $1600.3 | $298.3 |
| Other shareholder equity | $5130 | $5016.9 | $4876.2 | -$59.1 |
| Total shareholder equity | $5016.9 | $4876.2 | $4218.6 | |
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1011.4 | $1017.8 | ||
| Cost of revenue | $451.1 | $475.5 | ||
| Gross Profit | $560.3 | $542.3 | ||
| Operating activities | ||||
| Research & development | $64.1 | $74.6 | ||
| Selling, general & administrative | $240.3 | $244.6 | ||
| Total operating expenses | $316.3 | $331.9 | ||
| Operating income | $244 | $210.4 | ||
| Income from continuing operations | ||||
| EBIT | $272.6 | $243.8 | ||
| Income tax expense | $46.2 | $41.6 | ||
| Interest expense | $31.9 | $32.3 | ||
| Net income | ||||
| Net income | $194.5 | $169.9 | ||
| Income (for common shares) | $194.5 | $169.9 | ||
| (in millions $) | 28 Oct 2024 | 30 Oct 2023 | 24 Oct 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4030.3 | $4030.4 | $4862.8 | |
| Cost of revenue | ||||
| Gross Profit | $2267 | $2251 | $3014.8 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1296.8 | $1310 | $1366.6 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $75.6 | $220.1 | $286.2 | |
| Interest expense | -$15.1 | $24.3 | -$42.7 | |
| Net income | ||||
| Net income | $789.5 | $456 | $1302 | |
| Income (for common shares) | ||||
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $194.5 | $169.9 | $246.5 | |
| Operating activities | ||||
| Depreciation | $72.3 | $73.7 | $88.4 | |
| Business acquisitions & disposals | -$31.3 | |||
| Stock-based compensation | $14.6 | $25.8 | $28.7 | |
| Total cash flows from operations | $405.8 | $292.4 | $220 | |
| Investing activities | ||||
| Capital expenditures | -$43.9 | -$28 | -$38 | |
| Investments | -$3 | -$5 | -$34.5 | |
| Total cash flows from investing | -$781 | -$42.6 | -$38.5 | -$104.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$93.2 | $8.9 | -$667.3 | |
| Net borrowings | -$10.3 | -$10.4 | -$260.3 | |
| Total cash flows from financing | -$1108.6 | -$103.8 | -$4.2 | -$943.8 |
| Effect of exchange rate | $8.9 | -$0.3 | -$1.8 | $4.4 |
| Change in cash and equivalents | -$595.5 | $259.1 | $247.9 | -$823.6 |
| (in millions $) | 28 Oct 2024 | 30 Oct 2023 | 24 Oct 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $1871.5 | |||
| Operating activities | ||||
| Depreciation | $406.9 | |||
| Business acquisitions & disposals | -$1164.7 | |||
| Stock-based compensation | $65 | |||
| Total cash flows from operations | $2330.4 | |||
| Investing activities | ||||
| Capital expenditures | -$162.7 | |||
| Investments | ||||
| Total cash flows from investing | -$781 | -$152.1 | -$206.3 | -$1329.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$358.5 | |||
| Net borrowings | -$113.4 | |||
| Total cash flows from financing | -$1108.6 | -$483.2 | -$756 | -$529.8 |
| Effect of exchange rate | $8.9 | $0.3 | $5.8 | -$1.7 |
| Change in cash and equivalents | -$595.5 | $416.2 | $1169.2 | $469.3 |
News
Fundamentals
| Market cap | $17.41B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 232.27M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.69 |
| Quick ratio | 3.03 |